Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

119
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
119
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

170
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
170
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

119
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
119
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

203
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
203
Actuarial Approach01:20

Actuarial Approach

71
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
71

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

Blood cancer journal·2026
Same author

WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

Blood cancer journal·2026
Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

Expert Validation of an Artificial Intelligence-Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer.

JCO oncology practice·2026
Same author

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i>-Mutant Melanoma.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 20, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K

Improving Collection and Analysis of Overall Survival Data.

Lisa R Rodriguez1, Nicole J Gormley1, Ruixiao Lu2,3

  • 1U.S. Food and Drug Administration, Silver Spring, Maryland.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 22, 2024
PubMed
Summary

Improving cancer care requires robust overall survival (OS) data in clinical trials. This study proposes best practices for collecting and analyzing OS to better assess the true benefit-risk of new anticancer therapies.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

244
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Related Experiment Videos

Last Updated: Jun 20, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

244
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Anticancer therapies have improved patient survival, but challenges remain in evaluating new treatments.
  • Overall survival (OS) is the gold standard endpoint, but reliance on earlier endpoints may not correlate with OS.
  • Inadequate OS data collection in trials complicates benefit-risk assessments for novel cancer therapies.

Purpose of the Study:

  • To highlight the importance of rigorous overall survival (OS) data in cancer clinical trials.
  • To propose statistical methodologies and best practices for improving OS data collection and analysis.
  • To enhance the evaluation of benefit-risk for novel anticancer therapies.

Main Methods:

  • Review of current practices in cancer clinical trial endpoint selection.
  • Proposal of best practices for prospective OS data collection.
  • Recommendations for defining OS detriment and prespecifying OS analysis plans.

Main Results:

  • Many registrational trials lack adequate planning for OS data collection and analysis.
  • Improved OS data rigor is crucial for accurate benefit-risk assessments.
  • Novel statistical approaches can enhance the evaluation of OS data.

Conclusions:

  • Strengthening the collection and analysis of overall survival (OS) data is essential for cancer drug development.
  • Implementing proposed best practices will improve the interpretation of novel therapy benefits and risks.
  • Enhanced OS data utilization supports informed regulatory decisions and patient care.